Clinical Trial Search

Primary: Quality of Life as Measured by the Breast Q — 61.9; 57.6; 74.2; 64.2 score on a scale

Primary: Local Recurrence — 3.1 percentage of participants

Primary: Behavioral BC Risk With an Educational Intervention for Prevention — 8.10; 8.15 units on a scale

Primary: Knowledge of Breast Cancer Risk Factors — 48.9; 56.4 units on a scale

Primary: Number of Patients With Pathological Complete Response — 2 participants

Primary: Progression-free Survival (PFS) — 6.6; 3.8 Months — p=0.12

Primary: Change in Percent of Breast Epithelial Cells Staining Positive for Ki-67 — -1.2; -2.0 percentage of cells staining positive — p=0.71

Primary: Positive Margin Rate — 2 Participants

Primary: Number of Participants With a Change in Ki-67 Level — 15; 5; 3 Participants — p=0.004

Primary: Feasibility of an Educational Intervention: Adherence to the Intervention — 99; 83 Participants

Primary: MRI Diagnostic Yield of Cancers in the Contralateral Breast — 30; 114; 3; 822 Participants

Primary: Number of Participant Ovarian Insufficiency (Without of Menses for 12 Months) After Breast Cancer Diagnosis — 27; 11 Participants

Primary: Number of Patients With Treatment Emergent Adverse Events Occurring in Two or More Patients [Safety] — 24; 11; 8; 7 Participants

Primary: Percent Change in Mammographic Density at 1 Year on Exemestane — -2.4 percent change from baseline

Primary: Collect Data to Refine and Verify the Tumor Detection Algorithm. — 11.3 Percentage

Primary: Overall Survival — 82; 83 percentage of alive at 10 years — p=0.38

Primary: Mammographic Density — 22.71; 21.84; 22.09; 21.13 Percent

Primary: Number of Participants Experiencing Acute, Late Skin, and Subcutaneous Toxicity — 0 Participants

Primary: The Number of Evaluable Patients With Complete Response or Partial Response or Stable Disease for ≥10 Weeks From the First Infusion (6 Weeks After the Second Infusion)…

Primary: Number of Breast Cancers Detected — 279; 27 cancers detected

Primary: Client Satisfaction Questionnaire — 29.7; 27.9 score on a scale

Primary: Accuracy of CEM for Incremental Cancer Detection in the Ipsilateral and Contralateral Breasts. — 41.4 % of malignancy in new CEM lesions

Primary: (Phase A Only) Selection of Dose of LUM015 to be Used in Future Breast Trials — 2.1; 4.7; 4.2 Ratio

Primary: Number of Participants With Adverse Events — 9; 20 Participants

Primary: COVID-19 Vaccination on Contralateral vs Ipsilateral Arm — 432; 435; 331; 122 Participants

Primary: Test the Clinical Effectiveness of Concurrent Paclitaxel and Radiation in a Multiethnic Cohort

Primary: Number of Participants With a Pathological Complete Response — 21; 24; 99; 89 participants

Primary: Correlation of Vitamin D Levels, Prognostic Factors, and Gene Expression Profile in Patients With Breast Cancer — 0; 0; 0; 0 percentage of participants

Primary: Residual Motion During Deep Inspiratory Breath-Hold (DIBH) — 0.27; 0.27 mm

Primary: Identify a Feasible Schedule of Vaccination Relative to SoC Neoadjuvant Chemotherapy When the Chemovax Are Administered Concurrently. — 3; 2; 4; 2 Participants